Article

Arterial and venous resection for pancreatic adenocarcinoma: operative and long-term outcomes.

Division of Surgical Oncology, Department of Surgery and James Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, KY 40202, USA.
Archives of surgery (Chicago, Ill.: 1960) (Impact Factor: 4.3). 03/2009; 144(2):154-9. DOI: 10.1001/archsurg.2008.547
Source: PubMed

ABSTRACT Aggressive preoperative and intraoperative management may improve the resectability rates and outcomes for locally advanced pancreatic adenocarcinoma with venous involvement. The efficacy and use of venous resection and especially arterial resection in the management of pancreatic adenocarcinoma remain controversial.
Retrospective review of patients entered into prospective databases.
Two tertiary referral centers.
A retrospective review of 2 prospective databases of 593 consecutive pancreatic resections for pancreatic adenocarcinoma from January 1, 1999, through May 1, 2007.
Of the 593 patients, 36 (6.1%) underwent vascular resection at the time of pancreatectomy. Thirty-one of the 36 (88%) underwent venous resection alone; 3 (8%), combined arterial and venous resection; and 2 (6%), arterial resection (superior mesenteric artery resection) alone. Patients included 18 men and 18 women, with a median age of 62 (range, 42-82) years. The 90-day perioperative mortality and morbidity rates were 0% and 35%, respectively, compared with 2% and 39%, respectively, for the group undergoing nonvascular pancreatic resection (P = .34). Median survival was 18 (range, 8-42) months in the vascular resection group compared with 19 months in the nonvascular resection group. Multivariate analysis demonstrated node-positive disease, tumor location (other than head), and no adjuvant therapy as adverse prognostic variables.
In this combined experience, en bloc vascular resection consisting of venous resection alone, arterial resection alone, or combined vascular resection at the time of pancreatectomy for adenocarcinoma did not adversely affect postoperative mortality, morbidity, or overall survival. The need for vascular resection should not be a contraindication to surgical resection in the selected patient.

0 Followers
 · 
75 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Intraoperative ultrasonography (US) of the pancreas is a versatile technique that provides excellent spatial and contrast resolution and real-time imaging capabilities, making it useful for diagnostic imaging as well as for guidance of laparoscopic and open operative procedures. Intraoperative US may be used for applications such as staging and localizing tumors; performing regional metastatic surveys; documenting arterial and venous patency; identifying endocrine tumors; distinguishing pancreatitis from a neoplasm; and guiding biopsy, duct cannulation, and drainage of abscesses or cysts. The scanning approach and technique vary according to the application, with many different equipment and transducer options and sterilization methods available. With increasing clinical demands for intraoperative US, it is essential that radiologists be familiar with its uses and technique. In addition, to properly perform intraoperative US and accurately interpret the images, knowledge of normal and variant pancreatic and vascular anatomy and relevant landmarks is needed. Supplemental material available at http://radiographics.rsna.org/lookup/suppl/doi:10.1148/rg.307105051/-/DC1.
    Radiographics 11/2010; 30(7):1935-53. DOI:10.1148/rg.307105051 · 2.73 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Pancreatic cancer is still associated with a poor prognosis and remains – as the fourth leading cause of cancer-related mortality – a therapeutic challenge. Overall long-term survival is about 1–5%, in only 10–20% of pancreatic cancer patients potentially curative surgery is possible, increasing 5-year survival rates to approximately 20–25%. Pancreatic surgery is a technically challenging procedure and has significantly changed during the past decades with regard to technical aspects as well as perioperative care. METHODS: The current state of pancreatic cancer surgery is summarized with regard to standard indications and extended approaches. The available literature including randomized controlled trials and meta-analyses are included in this review article. RESULTS: Standardized resections are well established and can be carried out with low morbidity and mortality below 5% in high-volume institutions. Furthermore, there is growing evidence that also more extended resections including multivisceral approaches, vessel reconstructions or surgery for tumor recurrence can be carried out safely with favorable outcome. In addition, the impact of adjuvant treatment, especially chemotherapy, has increased dramatically within recent years, leading to significantly improved survival in resected pancreatic cancer patients. CONCLUSIONS: Pancreatic resections are the basis of any curative approach in pancreatic cancer treatment and can be performed with low morbidity and mortality in high-volume institutions. Furthermore, pancreatic cancer needs to be in an interdisciplinary approach to achieve best results. GRUNDLAGEN: Das Pankreascarcinom – als vierthäufigste Ursache der krebssassoziierten Mortaliät in der westlichen Welt – stellt aufgrund seiner schlechten Prognose mit einem Langzeitüberleben von 1–5 % nach wie vor eine therapeutische Herausforderung dar. Bei ca. 10–20 % der Patienten ist eine potenziell kurative Resektion möglich, wodurch 5-Jahres Überlebensraten von 20–25 % erreicht werden können. Pankreasresektionen sind operativ aufwändige Eingriffe. In den letzten Jahrzehnten hat sich die Pankreaschirurgie grundlegend gewandelt, sowohl im Hinblick auf technische Aspekte, als auch auf die perioperative Patientenbetreuung. METHODIK: Der aktuelle Stand der Pankreaschirurgie wird mit Blick auf Standardeingriffe, als auch erweiterte Indikationen unter Einschluss der verfügbaren Literatur mit randomisierten Studien und Metaanalysen im Überblick dargestellt. ERGEBNISSE: Standardresektionen beim Pankreascarcinom sind heute mit geringer chirurgischer Morbidität und Mortalitätsraten von unter 5 % in entsprechenden Zentren möglich. Darüber hinaus können auch erweiterte Eingriffe wie Gefäß-, Multiviszeral- und Rezidivresektionen sicher und mit gutem Outcome durchgeführt werden. Die postoperative adjuvante Therapie hat in den letzten Jahren einen großen Stellenwert in der Therapie des Pankreascarcinoms gewonnen, wodurch die Prognose deutlich verbessert wird. SCHLUSSFOLGERUNGEN: Die chirurgische Resektion stellt die Grundlage einer potenziell kurativen Therapie beim Pankreascarcinom dar und kann heutzutage in Zentren mit niedriger Morbidität und Mortalität durchgeführt werden. Die chirurgische Therapie muss hierbei in ein interdisziplinäres onkologisches Konzept eingebunden werden, um bestmögliche Ergebnisse zu erzielen. KeywordsPancreatic cancer-Surgical therapy-Indications-Complications SchlüsselwörterPankreascarcinom-Chirurgische Therapie-Indikationen-Komplikationen
    European Surgery 12/2009; 41(6):293-299. DOI:10.1007/s10353-009-0498-1 · 0.26 Impact Factor
  • Il Giornale di chirurgia 35(1-2):5-14.